Core Points - Columbus Circle Capital Corp I ("BRR") and ProCap BTC, LLC have announced the approval of their business combination by BRR's shareholders [1] - The business combination is expected to close on or about December 5, 2025, with the new public company to be named ProCap Financial, Inc. [2] - ProCap BTC has raised over $750 million from investors and aims to improve the financial lives of 1 billion people through its services [5] Company Overview - Columbus Circle Capital Corp I is a blank check company formed for mergers and acquisitions, led by experienced investment bankers [4] - ProCap BTC is a financial services firm leveraging bitcoin, focusing on innovative financial products [5] Transaction Details - A Current Report on Form 8-K will be filed to disclose the full voting results related to the business combination [3] - The new company's common stock is expected to trade on the Nasdaq Global Market under the symbol "BRR" after the transaction closes [2]

Core Insights - NovaBridge Biosciences announced new data from the expanded Phase 1 dosing study for ragistomig, a bispecific antibody targeting 4-1BB and PD-L1, to be presented at ESMO-IO 2025 [1][2] - The study successfully extended the therapeutic window for ragistomig, demonstrating strong anti-tumor efficacy and improved tolerability, including enhanced hepatic safety [2][3] - Ragistomig aims to provide new treatment options for patients resistant to checkpoint inhibitors, a significant drug class in cancer therapy [3][5] Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with clinical development [8] - The company is developing a differentiated pipeline, including ragistomig and givastomig, targeting various cancers and conditions [8][9] - Ragistomig is being developed in collaboration with ABL Bio, utilizing advanced bispecific antibody technology to minimize off-tumor toxicity [5][6] Clinical Study Details - The Phase 1 study of ragistomig is ongoing in the U.S. and South Korea, with a primary focus on defining dose-limiting toxicity and adverse event profiles [5][6] - The new dosing schedule, Q6W, has shown promising results in PD-L1 non-responders, balancing safety and sustained efficacy [6][7] - Interim results, including immunological data, are expected to be presented at the upcoming ESMO-IO meeting [6][7]

Core Points - Regentis Biomaterials Ltd. has announced the pricing of its initial public offering (IPO) of 1,250,000 ordinary shares at $8.00 per share, aiming for gross proceeds of $10 million before expenses [1][3] - The ordinary shares are set to begin trading on the NYSE American under the symbol "RGNT" on December 4, 2025, with the offering expected to close around December 5, 2025 [2] - The company plans to utilize the net proceeds primarily for development activities, including completing its pivotal trial and preparing for PMA submission for its product GerlinC, as well as for corporate purposes such as debt repayment [3] Company Overview - Regentis Biomaterials Ltd. focuses on regenerative medicine, specifically developing innovative tissue repair solutions to enhance patient health and quality of life [6] - The company's lead product, GelrinC, is a cell-free hydrogel designed for treating articular knee cartilage injuries and has received CE mark approval in Europe [6] - Regentis aims to commercialize GelrinC in Europe while also working towards obtaining FDA approval in the United States [6]

Core Viewpoint - Monument Mining Limited has announced positive initial results from its expansion drilling program at the Selinsing Gold Mine, indicating potential for increased gold resources and an extended mine life [1][2][8]. Drilling Program Overview - The Buffalo Reef/Felda mine expansion drilling program consists of 118 planned drill holes totaling 17,477 meters, with 109 holes for 15,377 meters at Buffalo Reef and 9 holes for 2,100 meters at Selinsing [7][36]. - The first 27 drill holes have been completed, totaling 2,952 meters, with assay results for 16 holes received and 11 pending [3][15]. Significant Assay Results - Notable assay results include: - MBRRC579: 22m @ 0.86g/t Au from 2m, including 1m @ 1.41g/t Au from 2m and 6m @ 1.9g/t Au from 8m [6][33]. - MBRRCDD01: 5m @ 2.01g/t Au & 0.47% Sb from 149m and 1m @ 1.14g/t Au & 0.2% Sb from 160m [34][51]. - MBRDD600: 4m @ 3.42g/t Au & 0.49% Sb from 55m [34][51]. Expansion Drilling Objectives - The objective of the expansion drilling is to increase gold resources and potentially extend the life of the Selinsing Gold Mine [2][9]. - The Buffalo Reef/Felda expansion target area covers 115 acres, aiming to evaluate the potential to extend currently defined mineral resources [2][17]. Budget and Timeline - The company has budgeted USD $2.5 million for the completion of both expansion drilling programs, targeting full completion by the end of June 2026 [8][43]. - The mine expansion drilling is expected to be completed by March 2026, with final assay results anticipated by the end of June 2026 [8][43]. Current Progress and Future Plans - The drilling program has been accelerated with the addition of two diamond drilling rigs to meet the schedule [16][27]. - An updated geological model and resource estimate are expected to be completed by October 2026 [16][43]. Selinsing Mine Expansion Drilling - The Selinsing mine expansion drilling program consists of 9 drill holes for 2,100 meters, with Stage 1 testing high-grade depth extensions and Stage 2 focusing on dip and strike extensions outside the expanded pit shell [36][41][42].

SINGAPORE, Dec. 03, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Jason Leow as a Senior Managing Director within the firm’s Strategic Communications segment. Mr. Leow, who is based in Singapore, brings more than 25 years of experience in financial communications, C-suite advisory and stakeholder engagement across Asia, Europe and the United States. In his role at FTI Consulting, he will work closely with the Asia Leadership Team and the firm’s global Senior Ma ...

VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mustang Energy Corp. (CSE: MEC, OTC: MECPF, FRA: 92T) (the “Company” or “Mustang”) is pleased to announce that it has staked two new mineral exploration properties in Newfoundland and Labrador — the Onyx Uranium Project (the “Onyx Project”) in southern Newfoundland and the Bridal Veil Copper–Silver Project (the “Bridal Veil Project”) in central Newfoundland — consisting of a combined 446 claims totaling approximately 3,875 hectares. Together, th ...

Proceeds will be used to continue growing and upgrading the Mineral Resource and advance Upscaled Economic Studies in lead up to a Final Investment DecisionNot for distribution to U.S. news wire services or dissemination in the United States. Green Bay Copper-Gold Project, Canada FireFly has received firm commitments totalling approximately A$134.1m (before costs) via a Charity Flow-Through Placement, Institutional Placement, and Canadian bought deal financingFireFly also intends to undertake a non-underwri ...

NOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN U.S. OR FOR DISSEMINATION IN U.S. MISSISSAUGA, Ontario, Dec. 03, 2025 (GLOBE NEWSWIRE) -- KP Tissue Inc. (KPT) (TSX: KPT) announced today that Kruger Products Inc. (“KPI”) has, pursuant to an underwriting agreement entered into today, agreed to issue and sell CDN $165 million principal amount of 6.250% Senior Unsecured Notes (the “Notes”) due December 10, 2032 by way of private placement (the “Offering”). Interest on the Notes is payable semi-annually in arrears ...

Core Insights - Mesoblast Limited is a global leader in allogeneic cellular medicines for inflammatory diseases and is participating in the Piper Sandler 37th Annual Healthcare Conference in New York from December 2–4, 2025 [1][2] Company Overview - Mesoblast specializes in developing allogeneic (off-the-shelf) cellular medicines aimed at treating severe and life-threatening inflammatory conditions, utilizing a proprietary mesenchymal lineage cell therapy technology platform [3] - The company has a strong intellectual property portfolio with over 1,000 granted patents or patent applications, providing commercial protection extending through at least 2044 in major markets [6] Product Development - Mesoblast's Ryoncil (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older [4] - The company is developing additional therapies for various inflammatory diseases, including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, as well as rexlemestrocel-L for heart failure and chronic low back pain [5] Manufacturing Capabilities - Mesoblast employs proprietary manufacturing processes that yield industrial-scale, cryopreserved, off-the-shelf cellular medicines, ensuring these therapies are readily available to patients worldwide [7] Global Presence - The company operates in Australia, the United States, and Singapore, and is listed on both the Australian Securities Exchange (MSB) and Nasdaq (MESO) [8]

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early stage New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States TOKYO and CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Ha ...